2-((2-(2-(3-fluoropyrrolidin-1-yl)ethyl)-1H-inden-3-yl)methyl)pyrazine | 1273545-40-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 英文名称: 2-((2-(2-(3-fluoropyrrolidin-1-yl)ethyl)-1H-inden-3-yl)methyl)pyrazine
• 英文别名: 2-[[2-[2-(3-fluoropyrrolidin-1-yl)ethyl]-3H-inden-1-yl]methyl]pyrazine
• CAS: 1273545-40-6
• 化学式: C₂₀H₂₂FN₃
• 分子量: 323.413
• InChiKey: ZMXXHEQIAQJFTR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  29
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-(2-(3-fluoropyrrolidin-1-yl)-2-oxoethyl)-2,3-dihydro-1H-inden-1-one 在 盐酸 、 lithium aluminium tetrahydride 、 二苯甲酮 、 potassium tert-butylate 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 苯 为溶剂， 反应 3.0h， 生成 2-((2-(2-(3-fluoropyrrolidin-1-yl)ethyl)-1H-inden-3-yl)methyl)pyrazine
  参考文献：
  名称：

  Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6

  摘要：

  Structure-activity relationship studies were conducted to reduce CYP2D6-mediated metabolism in a series of indene H-1-antihistamines. Reductions in pK(a) via incorporation of a beta-fluoro substituent or a heteroaryl moiety were shown to reduce contributions to metabolism through this pathway. Several compounds, including 8l, 8o, and 12f were identified with promising primary in vitro profiles and reduced biotransformation via CYP2D6. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.053

文献信息

• [EN] SLEEP INDUCING COMPOUNDS AND METHODS RELATING THERETO<br/>[FR] COMPOSES INDUCTEURS DE SOMMEIL ET METHODES ASSOCIEES
  申请人：NEUROCRINE BIOSCIENCES INC

  公开号：WO2005097093A1

  公开（公告）日：2005-10-20

  Compounds having the following structure: (I) including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, L1, L2 and n are as defined herein. Pharmaceutical compositions containing one or more compounds of structure (I), as well as methods relating to the use thereof, including methods for treating insomnia, inducing sleep or inducing sedation or hypnosis, are also disclosed.

  具有以下结构的化合物：(I) 包括立体异构体、前药和其药用可接受的盐，其中R1、R2a、R2b、R3、R4、R5a、R5b、L1、L2和n如本文所定义。包含一个或多个结构(I)的化合物的药物组合物，以及与其使用相关的方法，包括用于治疗失眠、诱导睡眠或诱导镇静或催眠的方法，也被披露。
• Sleep inducing compounds and methods relating thereto
  申请人：Moree J. Wilna (Willy)

  公开号：US20050277645A1

  公开（公告）日：2005-12-15

  Compounds having the following structure: including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein R 1 , R 2a , R 2b , R 3 , R 4 , R 5a , R 5b , L 1 , L 2 and n are as defined herein. Pharmaceutical compositions containing one or more compounds of structure (I), as well as methods relating to the use thereof, including methods for treating insomnia, inducing sleep or inducing sedation or hypnosis, are also disclosed.

  以下具有以下结构的化合物，包括立体异构体，前药和其药物可接受的盐，其中R1，R2a，R2b，R3，R4，R5a，R5b，L1，L2和n的定义如下。还公开了含有结构（I）中一种或多种化合物的制药组合物，以及与其使用相关的方法，包括用于治疗失眠，诱导睡眠或诱导镇静或催眠的方法。